NCT03994393 2023-04-21
ILLUMINATE
University of Sydney
Phase 2 Unknown
Clinical Trials
6 trialsNCT03975114 2023-03-24
MILES-5
National Cancer Institute, Naples
Phase 2 Unknown
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT02588131 2015-10-27
A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)
Italian Network for Tumor Biotherapy Foundation
Phase 2 Unknown
NCT01655888 2012-08-02
The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma
Azienda Ospedaliera Universitaria Senese
Phase 2 Unknown
NCT01649024 2012-07-25
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
Azienda Ospedaliera Universitaria Senese
Phase 2 Unknown